134 related articles for article (PubMed ID: 25749380)
1. Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer.
Galdiero F; Romano A; Pasquinelli R; Pignata S; Greggi S; Vuttariello E; Bello AM; Calise C; Scaffa C; Pisano C; Losito NS; Fusco A; Califano D; Chiappetta G
Oncotarget; 2015 Aug; 6(22):19328-35. PubMed ID: 25749380
[TBL] [Abstract][Full Text] [Related]
2. [Overexpression of high mobility group A2 and its correlation with microRNA let-7 family in serous ovarian cancers].
Yang J; Zhang Q; Dong JQ; Chang XH; He XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):749-54. PubMed ID: 23073586
[TBL] [Abstract][Full Text] [Related]
3. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
[TBL] [Abstract][Full Text] [Related]
5. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.
Komatsu H; Oishi T; Itamochi H; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Sawada M; Wakahara M; Umekita Y; Harada T
Int J Gynecol Cancer; 2017 Sep; 27(7):1325-1332. PubMed ID: 28557832
[TBL] [Abstract][Full Text] [Related]
6. Regulation of HMGA2 and KRAS genes in epithelial ovarian cancer by miRNA hsa-let-7d-3p.
Gunel T; Dogan B; Gumusoglu E; Hosseini MK; Topuz S; Aydinli K
J Cancer Res Ther; 2019; 15(6):1321-1327. PubMed ID: 31898667
[TBL] [Abstract][Full Text] [Related]
7. STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.
Wu J; Lai M; Shao C; Wang J; Wei JJ
Oncol Rep; 2015 Sep; 34(3):1494-502. PubMed ID: 26165228
[TBL] [Abstract][Full Text] [Related]
8. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
9. Circulating cell-free high mobility group AT-hook 2 mRNA as a detection marker in the serum of colorectal cancer patients.
Sahengbieke S; Wang J; Li X; Wang Y; Lai M; Wu J
J Clin Lab Anal; 2018 May; 32(4):e22332. PubMed ID: 28948632
[TBL] [Abstract][Full Text] [Related]
10. BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.
Han W; Zhang Y; Niu C; Guo J; Li J; Wei X; Jia M; Zhi X; Yao L; Meng D
Cancer Lett; 2019 Mar; 445():45-56. PubMed ID: 30654010
[TBL] [Abstract][Full Text] [Related]
11. Cyclin I mRNA expression correlates with kinase insert domain receptor expression in human epithelial ovarian cancer.
Cybulski M; Jeleniewicz W; Nowakowski A; Stenzel-Bembenek A; Tarkowski R; Kotarski J; Stepulak A
Anticancer Res; 2015 Feb; 35(2):1115-9. PubMed ID: 25667501
[TBL] [Abstract][Full Text] [Related]
12. Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Adv Exp Med Biol; 2016; 924():3-8. PubMed ID: 27753009
[TBL] [Abstract][Full Text] [Related]
13. The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas.
Yan J; Zhang Y; Shi W; Ren C; Liu Y; Pan Y
Tumour Biol; 2016 Jan; 37(1):823-8. PubMed ID: 26250458
[TBL] [Abstract][Full Text] [Related]
14. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
Lancaster JM; Sayer RA; Blanchette C; Calingaert B; Konidari I; Gray J; Schildkraut J; Schomberg DW; Marks JR; Berchuck A
Int J Gynecol Cancer; 2006; 16(4):1529-35. PubMed ID: 16884361
[TBL] [Abstract][Full Text] [Related]
15. A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer.
Zhu T; Gao W; Chen X; Zhang Y; Wu M; Zhang P; Wang S
Int J Gynecol Cancer; 2017 Jan; 27(1):3-10. PubMed ID: 27636713
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
17. HMGA2 gene is a promising target for ovarian cancer silencing therapy.
Malek A; Bakhidze E; Noske A; Sers C; Aigner A; Schäfer R; Tchernitsa O
Int J Cancer; 2008 Jul; 123(2):348-356. PubMed ID: 18452175
[TBL] [Abstract][Full Text] [Related]
18. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma.
Guo F; Tian J; Lin Y; Jin Y; Wang L; Cui M
J Int Med Res; 2013 Oct; 41(5):1456-61. PubMed ID: 23963852
[TBL] [Abstract][Full Text] [Related]
19. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma.
Mahajan A; Liu Z; Gellert L; Zou X; Yang G; Lee P; Yang X; Wei JJ
Mod Pathol; 2010 May; 23(5):673-81. PubMed ID: 20228781
[TBL] [Abstract][Full Text] [Related]
20. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
